222 related articles for article (PubMed ID: 37489561)
1. The efficacy and safety of roxadustat for anemia in patients with dialysis-dependent chronic kidney disease: a systematic review and meta-analysis.
Zhou Q; Mao M; Li J; Deng F
Ren Fail; 2023 Dec; 45(1):2195011. PubMed ID: 37489561
[TBL] [Abstract][Full Text] [Related]
2. Roxadustat (FG-4592) treatment for anemia in dialysis-dependent (DD) and not dialysis-dependent (NDD) chronic kidney disease patients: A systematic review and meta-analysis.
Liu J; Zhang A; Hayden JC; Bhagavathula AS; Alshehhi F; Rinaldi G; Kontogiannis V; Rahmani J
Pharmacol Res; 2020 May; 155():104747. PubMed ID: 32171893
[TBL] [Abstract][Full Text] [Related]
3. Safe and Effective Treatment for Anemic Patients With Chronic Kidney Disease: An Updated Systematic Review and Meta-Analysis on Roxadustat.
Tang M; Zhu C; Yan T; Zhou Y; Lv Q; Chuan J
Front Pharmacol; 2021; 12():658079. PubMed ID: 34276361
[No Abstract] [Full Text] [Related]
4. Efficacy and safety of roxadustat for anaemia in dialysis-dependent and non-dialysis-dependent chronic kidney disease patients: A systematic review and meta-analysis.
Zheng L; Tian J; Liu D; Zhao Y; Fang X; Zhang Y; Liu Y
Br J Clin Pharmacol; 2022 Mar; 88(3):919-932. PubMed ID: 34428860
[TBL] [Abstract][Full Text] [Related]
5. A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Naïve Chronic Kidney Disease Patients Not on Dialysis.
Akizawa T; Yamaguchi Y; Otsuka T; Reusch M
Nephron; 2020; 144(8):372-382. PubMed ID: 32580188
[TBL] [Abstract][Full Text] [Related]
6. Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan.
Akizawa T; Iwasaki M; Yamaguchi Y; Majikawa Y; Reusch M
J Am Soc Nephrol; 2020 Jul; 31(7):1628-1639. PubMed ID: 32493693
[TBL] [Abstract][Full Text] [Related]
7. A network meta-analysis of the efficacy of hypoxia-inducible factor prolyl-hydroxylase inhibitors in dialysis chronic kidney disease.
Chen J; Shou X; Xu Y; Jin L; Zhu C; Ye X; Mei Z; Chen P
Aging (Albany NY); 2023 Mar; 15(6):2237-2274. PubMed ID: 36988549
[TBL] [Abstract][Full Text] [Related]
8. The Efficacy and Safety of Roxadustat for Anemia in Patients With Chronic Kidney Disease: A Meta-Analysis.
Wang L; Yin H; Yang L; Zhang F; Wang S; Liao D
Front Pharmacol; 2022; 13():779694. PubMed ID: 35559232
[No Abstract] [Full Text] [Related]
9. Roxadustat regulates iron metabolism in dialysis-dependent and non-dialysis-dependent chronic kidney disease patients: A meta-analysis.
Hou YP; Wang C; Mao XY; Zhang MZ; Li B
J Formos Med Assoc; 2022 Nov; 121(11):2288-2299. PubMed ID: 35871036
[TBL] [Abstract][Full Text] [Related]
10. Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study.
Fishbane S; El-Shahawy MA; Pecoits-Filho R; Van BP; Houser MT; Frison L; Little DJ; Guzman NJ; Pergola PE
J Am Soc Nephrol; 2021 Mar; 32(3):737-755. PubMed ID: 33568383
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and Cardiovascular Safety of Roxadustat in Dialysis-Dependent Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies.
Barratt J; Sulowicz W; Schömig M; Esposito C; Reusch M; Young J; Csiky B
Adv Ther; 2021 Oct; 38(10):5345-5360. PubMed ID: 34523074
[TBL] [Abstract][Full Text] [Related]
12. Roxadustat for the Maintenance Treatment of Anemia in Patients with End-Stage Kidney Disease on Stable Dialysis: A European Phase 3, Randomized, Open-Label, Active-Controlled Study (PYRENEES).
Csiky B; Schömig M; Esposito C; Barratt J; Reusch M; Valluri U; Sulowicz W
Adv Ther; 2021 Oct; 38(10):5361-5380. PubMed ID: 34537926
[TBL] [Abstract][Full Text] [Related]
13. Risk Factors for Thromboembolic Events in Patients With Dialysis-Dependent CKD: Pooled Analysis of Phase 3 Roxadustat Trials in Japan.
Hamano T; Yamaguchi Y; Goto K; Mizokawa S; Ito Y; Dellanna F; Barratt J; Akizawa T
Adv Ther; 2024 Apr; 41(4):1526-1552. PubMed ID: 38363463
[TBL] [Abstract][Full Text] [Related]
14. Risk Factors for Thromboembolic Events in Patients With Dialysis-Dependent CKD: Pooled Analysis of Four Global Roxadustat Phase 3 Trials.
Hamano T; Yamaguchi Y; Goto K; Martin S; Jiletcovici A; Dellanna F; Akizawa T; Barratt J
Adv Ther; 2024 Apr; 41(4):1553-1575. PubMed ID: 38363466
[TBL] [Abstract][Full Text] [Related]
15. Risk of infection in roxadustat treatment for anemia in patients with chronic kidney disease: A systematic review with meta-analysis and trial sequential analysis.
Chong S; Xie Q; Ma T; Xiang Q; Zhou Y; Cui Y
Front Pharmacol; 2022; 13():967532. PubMed ID: 36188528
[No Abstract] [Full Text] [Related]
16. The efficacy and safety of roxadustat for anemia in patients with chronic kidney disease: a meta-analysis.
Zheng Q; Yang H; Fu X; Huang Y; Wei R; Wang Y; Liu YN; Liu WJ
Nephrol Dial Transplant; 2021 Aug; 36(9):1603-1615. PubMed ID: 33051677
[TBL] [Abstract][Full Text] [Related]
17. Roxadustat treatment for anemia in peritoneal dialysis patients: A randomized controlled trial.
Hou YP; Mao XY; Wang C; Xu ZH; Bu ZH; Xu M; Li B
J Formos Med Assoc; 2022 Feb; 121(2):529-538. PubMed ID: 34167878
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Cardiovascular Safety of Roxadustat for Treatment of Anemia in Patients with Non-Dialysis-Dependent CKD: Pooled Results of Three Randomized Clinical Trials.
Provenzano R; Szczech L; Leong R; Saikali KG; Zhong M; Lee TT; Little DJ; Houser MT; Frison L; Houghton J; Neff TB
Clin J Am Soc Nephrol; 2021 Aug; 16(8):1190-1200. PubMed ID: 34362786
[TBL] [Abstract][Full Text] [Related]
19. Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis.
Chen N; Hao C; Liu BC; Lin H; Wang C; Xing C; Liang X; Jiang G; Liu Z; Li X; Zuo L; Luo L; Wang J; Zhao MH; Liu Z; Cai GY; Hao L; Leong R; Wang C; Liu C; Neff T; Szczech L; Yu KP
N Engl J Med; 2019 Sep; 381(11):1011-1022. PubMed ID: 31340116
[TBL] [Abstract][Full Text] [Related]
20. Safety of Roxadustat Versus Erythropoiesis-Stimulating Agents in Patients with Anemia of Non-dialysis-Dependent or Incident-to-Dialysis Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies.
Barratt J; Dellanna F; Portoles J; Choukroun G; De Nicola L; Young J; Dimković N; Reusch M
Adv Ther; 2023 Apr; 40(4):1546-1559. PubMed ID: 36749544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
